Illumina Inc. stock drops 5.16 percent and underperforms competitors

7 articles · Updated · MarketWatch · Apr 29

Shares closed at $120.37 on Wednesday, marking a second consecutive day of losses and trading 22.61% below the 52-week high of $155.53.
Illumina's decline outpaced rivals like Labcorp, Charles River Laboratories, and Quest Diagnostics, as the S&P 500 and Dow Jones also slipped during a rough market session.
Trading volume for Illumina reached 1.7 million, surpassing its 50-day average, highlighting heightened activity amid broader market volatility.

Why is Wall Street punishing Illumina despite its strong cash flow and positive outlook?

Can Illumina's growth forecast survive its 30% revenue collapse in China?

Will the US BIOSECURE Act ultimately help or hurt Illumina's global ambitions?

As long-read sequencing surges, is Illumina's market dominance nearing its end?

Is the SomaLogic acquisition a big enough move to counter Illumina's core business threats?

Can a former competitor's CEO on the board steer Illumina through this crisis?